PPARA and metabolic dysfunction-associated steatohepatitis: Lanifibranor, a pan PPAR agonist that activates three PPARs, lowered the SAF-A score and relieved NASH in a recently published Phase 2b randomized, double-blind, placebo-controlled trial (115).